F Blanchon

2.0k total citations
44 papers, 808 citations indexed

About

F Blanchon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, F Blanchon has authored 44 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 12 papers in Epidemiology. Recurrent topics in F Blanchon's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (16 papers) and Lung Cancer Diagnosis and Treatment (16 papers). F Blanchon is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (16 papers) and Lung Cancer Diagnosis and Treatment (16 papers). F Blanchon collaborates with scholars based in France, French Polynesia and Switzerland. F Blanchon's co-authors include M Grivaux, J. Piquet, Mahmoud Zureik, Bernard Asselain, Francis Martin, J.-M. Chavaillon, T. Collon, D. Coëtmeur, Philippe David and B. Milleron and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

F Blanchon

38 papers receiving 788 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F Blanchon France 13 654 444 119 77 56 44 808
M Grivaux France 16 501 0.8× 405 0.9× 106 0.9× 69 0.9× 76 1.4× 84 750
Santi Barbera Italy 10 456 0.7× 632 1.4× 46 0.4× 72 0.9× 106 1.9× 17 978
Benoît Colinet Belgium 9 315 0.5× 193 0.4× 50 0.4× 70 0.9× 46 0.8× 22 512
A Ducoloné France 12 1.4k 2.1× 249 0.6× 62 0.5× 46 0.6× 160 2.9× 30 1.5k
V.E.P.P. Lemmens Netherlands 13 216 0.3× 498 1.1× 70 0.6× 52 0.7× 27 0.5× 27 811
Øystein Fløtten Norway 14 528 0.8× 626 1.4× 175 1.5× 122 1.6× 336 6.0× 33 1.1k
Sharma P. Riaz United Kingdom 8 310 0.5× 318 0.7× 120 1.0× 60 0.8× 8 0.1× 9 527
Hiroshi Wataya Japan 14 358 0.5× 289 0.7× 57 0.5× 101 1.3× 9 0.2× 41 558
P. P. A. Razenberg Netherlands 5 270 0.4× 210 0.5× 65 0.5× 41 0.5× 15 0.3× 7 463
Francovito Piantedosi Italy 7 472 0.7× 507 1.1× 43 0.4× 42 0.5× 124 2.2× 12 774

Countries citing papers authored by F Blanchon

Since Specialization
Citations

This map shows the geographic impact of F Blanchon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F Blanchon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F Blanchon more than expected).

Fields of papers citing papers by F Blanchon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F Blanchon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F Blanchon. The network helps show where F Blanchon may publish in the future.

Co-authorship network of co-authors of F Blanchon

This figure shows the co-authorship network connecting the top 25 collaborators of F Blanchon. A scholar is included among the top collaborators of F Blanchon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F Blanchon. F Blanchon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grivaux, M, François Goupil, Bernard Asselain, et al.. (2017). Stratégies thérapeutiques les 2 premières années après un diagnostic de cancer du poumon. ESCAP-2011-CPHG, étude en situation réelle réalisée dans les hôpitaux généraux français. Revue des Maladies Respiratoires. 34(9). 991–999. 7 indexed citations
2.
Monnet, I., Clarisse Audigier-Valette, Nicolas Girard, et al.. (2016). Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study. Lung Cancer. 98. 84–90. 4 indexed citations
3.
Piquet, J., J.-M. Chavaillon, Philippe David, et al.. (2013). High-risk patients following hospitalisation for an acute exacerbation of COPD. European Respiratory Journal. 42(4). 946–955. 83 indexed citations
4.
Locher, Chrystèle, D. Debieuvre, D. Coëtmeur, et al.. (2013). Major changes in lung cancer over the last ten years in France: The KBP-CPHG studies. Lung Cancer. 81(1). 32–38. 74 indexed citations
5.
Locher, Chrystèle, Dominique Herman, D. Debieuvre, et al.. (2012). Study KBP-2010-CPHG: Characteristics and management of 7,051 new cases of lung cancer managed in French general hospitals in 2010.. Journal of Clinical Oncology. 30(15_suppl). 1574–1574.
6.
Grivaux, M, Mahmoud Zureik, Bernard Asselain, et al.. (2011). Five-year survival for lung cancer patients managed in general hospitals. Revue des Maladies Respiratoires. 28(7). e31–e38. 32 indexed citations
7.
Chavaillon, J.-M., P. David, Martin Fortin, et al.. (2010). Mortalité intrahospitalière au cours des exacerbations aiguës de BPCO. Étude EABPCO-CPHG du Collège des pneumologues des hôpitaux généraux (CPHG). Revue des Maladies Respiratoires. 27(7). 709–716. 6 indexed citations
8.
9.
Piquet, J., J.-M. Chavaillon, P. David, et al.. (2009). Caractéristiques et prise en charge des exacerbations aiguës de BPCO hospitalisées. Étude EABPCO–CPHG du Collège des pneumologues des hôpitaux généraux. Revue des Maladies Respiratoires. 27(1). 19–29. 10 indexed citations
10.
Blanchon, F, M Grivaux, Mahmoud Zureik, et al.. (2006). CohorteKbp-2000-Cphg : évaluation des facteurs pronostiques de la survie du cancer bronchique primitif à 2 et 5 ans. Revue des Maladies Respiratoires. 23(2). 165–171. 12 indexed citations
11.
Grivaux, M, et al.. (2006). Métastases intestinales de carcinome broncho-pulmonaire. Revue des Maladies Respiratoires. 23(3). 273–276. 5 indexed citations
12.
Blanchon, F, M Grivaux, Bernard Asselain, et al.. (2006). 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. The Lancet Oncology. 7(10). 829–836. 92 indexed citations
13.
Collon, T., M Grivaux, P. Doré, et al.. (2004). Le cancer bronchique primitif non à petites cellules : analyse des 419 cas de tumeurs T1 (≤ 3 cm) de l’étude KBP-2000-CPHG. Revue de Pneumologie Clinique. 60(6). 333–343. 3 indexed citations
14.
Grivaux, M, P. Bombaron, François Lebas, et al.. (2004). Lung cancer among women in France.. Lung Cancer. 45(3). 279–287. 19 indexed citations
15.
Piquet, J., F Blanchon, M Grivaux, et al.. (2004). Le cancer bronchique primitif du sujet âgé en France. Revue des Maladies Respiratoires. 21(5). 70–78. 9 indexed citations
16.
17.
Thomas, P., O. Castelnau, D. Paillotin, et al.. (2001). Phase II Trial of Paclitaxel and Carboplatin in Metastatic Small-Cell Lung Cancer: A Groupe Français de Pneumo-Cancérologie Study. Journal of Clinical Oncology. 19(5). 1320–1325. 31 indexed citations
18.
Castelnau, O., M. Pérol, A. Vergnenègre, et al.. (1995). [Carboplatin-VP16 combination in non small cell lung cancers in the aged patient. A study of the French group in pneumology (GFPC)].. PubMed. 82(1). 63–6. 2 indexed citations
19.
Depierre, A, Claude Chastang, Élisabeth Quoix, et al.. (1994). Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial. Annals of Oncology. 5(1). 37–42. 184 indexed citations
20.
Carette, M.F., et al.. (1979). [Destroyed lung (author's transl)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 55(17-18). 843–53. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M Grivaux Breakdown of academic impact, for papers by Santi Barbera Breakdown of academic impact, for papers by Benoît Colinet Breakdown of academic impact, for papers by A Ducoloné Breakdown of academic impact, for papers by V.E.P.P. Lemmens Breakdown of academic impact, for papers by Øystein Fløtten Breakdown of academic impact, for papers by Sharma P. Riaz Breakdown of academic impact, for papers by Hiroshi Wataya Breakdown of academic impact, for papers by P. P. A. Razenberg Breakdown of academic impact, for papers by Francovito Piantedosi
Rankless by CCL
2026